NuSci Institute & Corp. – Trademark Portfolio

Entity Type: 03

NuSci Institute & Corp. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NUSCI. The owner is based in Walnut, CA.

348 Paseo Tesoro

Walnut, CA 91789

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NUSCI
NUSCI
Registered 2011

Trademark Classifications

NuSci Institute & Corp.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does NuSci Institute & Corp. have?

NuSci Institute & Corp. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does NuSci Institute & Corp. file in?

NuSci Institute & Corp. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What are NuSci Institute & Corp.'s most well-known trademarks?

NuSci Institute & Corp.'s registered trademark portfolio includes well-known marks such as NUSCI. These are among 1 currently registered trademark in the portfolio.

What is NuSci Institute & Corp.'s trademark registration success rate?

NuSci Institute & Corp. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.